Salt Lake City—PolarityTE, Inc., a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, announced that the pricing of an underwritten public offering of 2,031,250 shares of its common stock at a price to the public of $16.00 per share. Proceeds to PolarityTE, before underwriting discounts and commissions and estimated offering expenses payable by the company, are expected to be approximately $32.5 million. PolarityTE has granted the underwriters for the offering a 30-day option to purchase up to 304,687 additional shares of its common stock at the price to the public, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2018, subject to satisfaction of customary closing conditions.
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
PolarityTE intends to use the net proceeds from the offering for research and development of its products and product candidates, efforts toward commercialization and required registration or approval of its products and product candidates with applicable regulatory authorities and general corporate purposes.
The securities described above are being offered by PolarityTE pursuant to a registration statement (File No. 333-219202) which has been filed with and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022 or by e-mail at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.